ESMO Webinar-hero

Citeline analysts Millie Gray and Flora Mackay take a look at the high-impact abstracts, presented at ESMO 2023. They also address the most practice-changing data, putting it into context, and cover indications including HR+/HER- breast cancer, bladder cancer, gastric cancer, prostate cancer, NSCLC, and more.

Related resources

ESMO congress event logo held in Madrid 2023.
OCT 01, 2023
Article
Clinical

ESMO 2023 Insights

In this overview, we look at the clinical trial landscape for trials that had data presented at ESMO 2023.

Liquid drop coming out of a pipette.
MAY 01, 2023
Conference Report
商業化支援サービス

2023 Pre-ASCO Report

The Pharma R&D Annual Review 2023 Supplement looks at new active substances (NASs), drugs launched onto the market for the first time, during 2022

radiopharmaceuticals_for_cancer_resource-card-thumbnail
FEB 01, 2022
Article
Clinical

Radiopharmaceuticals: A New Approach to Cancer Treatment

Radiopharmaceutical therapy is an emerging targeted approach to treat cancer, whose potential with specific tumor-associated targets is being recognized.